EXQNF Stock UPDATES Exiqon As (EXQNF) 1.5000 08/11/2014 07:3

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Exiqon As (EXQNF) 1.5000 $EXQNF

Concise Analysis of the International qPCR and dPCR Instrumentation Market
M2 - Tue Mar 18, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2m2mm/qpcr_and_dpcr) has announced the addition of the "Concise Analysis of the International qPCR and dPCR Instrumentation Market" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Million. The Global market is further analyzed by the following Product Segments and End-Use Markets: Product Segments - qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction); End-Use markets - Educational/Research, Testing Laboratories, and Pharma. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 49 companies including many key and niche players such as: - Agilent Technologies - Biofire Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Cepheid - Eppendorf AG - Exiqon A/S - F. Hoffmann-La Roche Ltd. - Fluidigm Corporation - Illumina, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/ INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. MIDDLE EAST & AFRICA 7. LATIN AMERICA IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 49 (including Divisions/Subsidiaries - 51) - The United States (29) - Canada (1) - Japan (1) - Europe (19) - Germany (7) - The United Kingdom (2) - Spain (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/f2...r_and_dpcr

Global MicroRNA Market Report 2013 - Includes Forecasts to 2016
M2 - Fri Dec 20, 9:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/57rqjm/global_microrna) has announced the addition of the "Global MicroRNA Market Report 2013 - Includes Forecasts to 20" report to their offering. One of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests. A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. Thus, the Global MicroRNA market is witnessing the increasing use of microRNAs as biomarkers. Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market. The key vendors dominating this market space are: - Alnylam Pharmaceuticals Inc. - Exiqon A/S - Santaris Pharma A/S. Key Topics Covered: 01. Executive Summary 02. Scope of the Report 03. Market Research Methodology 04. List of Abbreviations 05. Introduction 06. Market Landscape 07. Global MicroRNA Research Market 08. Global MicroRNA Market 09. Global MicroRNA Market Segmentation 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/57...l_microrna

Global Companion Biomarkers in Drug Development Market Report 2013
M2 - Tue Dec 17, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/cxq2xl/companion) has announced the addition of the "Global Companion Biomarkers in Drug Development Market Report 2013" report to their offering. "Global Companion Biomarkers in Drug Development Market Report 2013", focuses on companion biomarkers, which are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. The report provides market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. This analysis also gives insights into the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. Key Topics Covered: 1. Overview 2. Introduction: Companion Diagnostics in Drug Development 3. Biomarker Development Tools 4. Market for Biomarkers in Drug Development 5. Imaging Biomarkers in Drug Discovery 6. Clinical Biomarkers Improving Trial Design 7. Biomarkers as Surrogate Endpoints 8. Market Size, Collaborations and Future Directions for Companion Diagnostics in Drug Development 9. Regulatory Issues for Biomarkers in Drug Development 10. Business Decisions Using Companion Biomarkers in Drug Development 11. Company Profiles Companies Mentioned: - Axontologic - Bristol-Myers Squibb Company - Cybrdi - Discerna - Exiqon A/S - Future Diagnostics - Gyros AB - Human Genome Sciences (GSK) - Ipsen - Johnson & Johnson - KOOPrime - Luminex - Multimetrix - Nuvera Biosciences - Oxonica - Pub Gene - Qiagen - Roche - Sygnis Pharma AG - Tyrian Diagnostic - ViaLogy - Wyeth - Zeptosens For more information visit http://www.researchandmarkets.com/research/cxq2xl/companion

Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan
GlobeNewswire - Mon Jul 08, 3:09AM CDT
Exiqon A/S (Copenhagen:EXQ), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.

Molecular Diagnostics in Infectious Disease Testing Report
M2 - Fri Jun 21, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z985r3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease. Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically import

RNA Interference (RNAi) - Global Strategic Business Report
M2 - Wed Feb 13, 6:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqz252/rna_interference) has announced the addition of the "RNA Interference (RNAi) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Outlook 2. Industry Overview 3. Market Outlook 4. Product Overview 5. Applications O




Scroll down for more posts ▼

Top 10 Most Recent News Articles

MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 92

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 93

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Harbour BioMed's LET003 Gets China's IND Green Light

Updated Category News Views 84

Muscle loss has become the awkward fact sitting beside every blockbuster obesity headline. Harbour BioMed's Nov. 18 announcement that China's National Medical Products Administration accepted its IND application for LET003 matters because the company is aiming directly at that problem: losing fat without giving away too much lean mass along the way. Acceptance Opens a...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 91

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Northstar's December Test: Metrics Over More Promises

Updated Category News Views 11

A shingle recycler earns its stripes when the machinery behaves, not when the slide deck does. Northstar Clean Technologies is putting Empower Calgary under a brighter light on December 1, pairing its third-quarter 2026 results with a comprehensive production update and a new set of operating metrics. For shareholders, especially those following OTCQB:ROOOF, this is the...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 35

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 72

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

MediPharm Labs: Strategic Steps for Enhanced Shareholder Value

Updated Category News Views 141

MediPharm Labs Announces Proxy Materials for Shareholder Meetings Toronto - MediPharm Labs Corp. (TSX: LABS) has filed comprehensive Management Information Circulars and proxy materials ahead of its upcoming Annual and Special Meeting. This meeting, pivotal for the future direction of the company, is set for June 16. Shareholders can expect to receive these materials...

Continue Reading
PRM Revitalizes Its Online Presence with Stylish Relaunch

Updated Category News Views 215

PRM Elevates Your Style with an Online Revamp In an exciting development for fashion enthusiasts, PRM, a trendsetting brand where luxury meets urban flair, has unveiled a newly revamped online store. This relaunch marks a significant transformation spearheaded with the expert assistance from industry professionals, aiming to elevate its presence in the European fashion...

Continue Reading
Why Companies Choose Altcoins Like ETH, SOL, and XRP Over Bitcoin

Updated Category News Views 188

Why Companies Are Opting for Altcoins in Their Treasury Strategies In recent times, publicly traded companies have increasingly embraced a wider array of cryptocurrencies beyond Bitcoin. Names like Ethereum, Solana, XRP, and Binance Coin are becoming commonplace in corporate treasuries. This trend reflects a significant shift in how businesses perceive and integrate these...

Continue Reading
Epson Launches Arm-Compatible Drivers for Advanced Scanning Solutions

Updated Category News Views 346

Epson's Commitment to Innovation in Scanning Technology Epson America, the top-selling scanner brand in the U.S., is proud to unveil Arm-compatible drivers for Windows in its extensive lineup of scanners. This groundbreaking step positions Epson as a leader in the scanning technology space, tailored for industries such as healthcare, finance, and enterprise solutions....

Continue Reading
Harnessing AI for Transformation: A Framework for Organizations

Updated Category News Views 240

Harnessing AI for Transformation: A Comprehensive Framework Artificial intelligence (AI) stands as one of the most revolutionary technologies in today’s world, yet many organizations grapple with moving from mere experiments to having a concrete enterprise strategy. A leading research and advisory firm has released a blueprint aimed at guiding both IT and business...

Continue Reading